Additionally, favorable outcomes with venetoclax were reported for genetic subtypes of pediatric AML including mutated CBFβ/MYH11, RUNX1-RUNX1T1, and CEBPA, while no benefit was reported for FLT3-AML [134]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.